Trends in Epilepsy Research
The Foundation for Angelamn Syndrome Therapeutics (FAST) launches a new biotech, GeneTx Biotherapeutics LLC (GeneTx), a subsidiary of FAST, for the development and commercialization of an investigational antisense drug, GTX-101, for the treatment of Angelman syndrome (AS), a rare genetic disorder characterized by epilepsy, impaired motor function and speech delays. Read More
A recent study published in the New England Journal of Medicine (NEJM) shows a purified cannabidiol (CBD) medication called Epidiolex may help to curb seizures in children and young adults with Dravet syndrome. Read More
David Cameron’s son Ivan was born with a neurological disorder that baffled doctors. He was later diagnosed with a rare epileptic syndrome, Ohtahara syndrome. Now, he writes, genomic testing can end the anguish of uncertainty.